FDA's Balancing Act: Early Hints at a Biosimilars
This article was originally published in RPM Report
Executive Summary
FDA opened the regulatory phase of the biosimilar debate by hearing from industry and other stakeholders about what an approval system should look like. But this information-gathering session wasn’t all one-sided: FDA officials offered some hints of what they are thinking too. And while there are some significant areas of disagreement—and outlier positions—there was also quite a bit of common ground.
You may also be interested in...
Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?
Much “Ado” About Biosimilars
The approval of Kadcyla gives Roche/Genentech yet another new breakthrough cancer therapy in the US. It also offers some clues about the future of biosimilars at FDA.
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.